ViGenCell KRX:308080KOSDAQ
바이젠셀 · Korean news coverage and regulatory filings, organized.
In Q3 2026, ViGenCell reported revenue of ₩566m, up 6972.9% year on year, and an operating loss of ₩2.6bn. ViGenCell (바이젠셀) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 4 with 8 articles. The most common catalyst was tech & capacity (2). It was most often mentioned alongside 글로벌테크놀로지 and L&C Bio.
Filing signals 4 quarters of losses Screener
ViGenCell today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates ViGenCell stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
ViGenCell quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩566m | +6972.9% | −₩2.6bn | −₩2.4bn |
| Q2 2026 | ₩571m | +91691.0% | −₩2.5bn | −₩2.3bn |
| Q1 2026 | ₩329m | – | −₩2.8bn | −₩2.6bn |
| Q4 2025 derived | ₩14m | -93.7% | −₩6.3bn | −₩6.1bn |
| Q3 2025 | ₩8m | +1500.2% | −₩2.4bn | −₩2.2bn |
| Q2 2025 | ₩1m | -98.9% | −₩5.7bn | −₩5.4bn |
| Q1 2025 | ₩0m | – | −₩2.7bn | −₩2.6bn |
| Q4 2024 derived | ₩223m | – | −₩3.7bn | −₩3.7bn |
ViGenCell ranks #2039 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
ViGenCell top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest ViGenCell news Korean headlines
-
MajorBaizenCell participates in Bio Europe seeking cell therapy technology transfer
1 more on this story · 1 outlets
-
Baigenzell knocks on door of Japanese regenerative medicine market with VC-101
1 more on this story · 1 outlets
-
Baigenzell participates in Bio Japan, exploring entry into Japanese regenerative medicine market
3 more on this story · 3 outlets
- Baigenzell participates in Bio Japan, pursuing global business development in Japanese regenerative medicine market머니투데이 · Oct 7 14:22
- Baigenzell participates in Bio Japan, targeting Japanese regenerative medicine market뉴스1 · Oct 7 15:25
- Baigenzell participates in Bio Japan, targeting Japanese regenerative medicine market핀포인트뉴스 · Oct 7 17:08